Enveda raised $311 million in a round that valued the AI biotechnology company at $2 billion, according to TechCrunch AI.
The company is already testing drugs for treating skin conditions and maintaining weight loss after discontinuing GLP-1 class medications.
The significance of the round lies in Enveda's transition from development to clinical trials: additional funding is intended to support advancing more nature-derived drug candidates. However, the available material does not specify which candidates or at what stages they are.
editorial commentary
Why it matters
A likely consequence is an expansion in the number of Enveda programs directed toward clinical trials. The next observable signal will be the disclosure of specific candidates, stages, and research timelines. Significant uncertainty remains as the source does not disclose investors, the round structure, or program details.